Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT.
Sax
Paul E
PE
D000480:Alkynes; D048588:Benzoxazines / Q000627:therapeutic use*; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000627:therapeutic use*; D003521:Cyclopropanes; D015658:HIV Infections / Q000209:etiology*; D006801:Humans; D000077592:Maraviroc; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D014230:Triazoles / Q000627:therapeutic use*
D000480:Alkynes; D048588:Benzoxazines; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D003521:Cyclopropanes; D018894:Reverse Transcriptase Inhibitors; D014230:Triazoles; C098320:efavirenz; D000077592:Maraviroc